- Home
- MYNZ
MYNZ
Mainz Biomed N.V.
as 07-26-2024 4:00pm EST
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
| Founded: | 2021 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.9M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.32 - $4.71 | Next Earning Date: | 08-13-2024 |
| Revenue: | $895,479 | Revenue Growth: | 69.00% |
| Revenue Growth (this year): | 67.4% | Revenue Growth (next year): | 191.13% |
Latest Mainz Biomed N.V. News
MYNZ Breaking Stock News: Dive into MYNZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Medical Device Network
17 days ago
Mainz Biomed seeks FDA breakthrough device status for colorectal cancer test
MT Newswires
17 days ago
Top Premarket Gainers
GlobeNewswire
18 days ago
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Benzinga
24 days ago
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
GlobeNewswire
24 days ago
Mainz Biomed Provides Half Year 2024 Corporate Update
GuruFocus.com
2 months ago
Catherine Wood's Strategic Acquisition of PagerDuty Inc Shares
Business Wire
2 months ago
ADM Animal Nutrition Expands Recall to Include Additional Lots of Various Feed Products
Compare MYNZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYNZ Mainz Biomed N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.